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1. Introduction 
Cardiovascular diseases that include atherosclerotic diseases; coronary artery disease, 
cerebrovascular disease and peripheral vascular disease, and cardiac functional diseases; 
congestive heart failure, left ventricular hypertrophy and arrhythmias, are very common 
in the general population and are the first cause of mortality (Wilson &Culleton, 1998, 
Culleton & Wilson, 1998). Moreover, patients with chronic renal failure have an increased 
risk of cardiovascular disease compared with the general population, and after 
stratification by age and gender, cardiovascular mortality is 10 to 20 times more frequent 
independently of treatment; predialysis, dialysis or after kidney transplantation (Foley et 
al, 1998). Kidney transplantation is the best therapy of end-stage renal disease by reducing 
cardiovascular mortality (McDonald &Russ, 2002, Ojo et al, 2000, Wolfe et al, 1999). But 
even after transplantation,  a recipient of 25 to 35 years of age has a 10 times higher risk of 
cardiovascular mortality than an individual of similar sex and gender without renal 
failure (Foley et al, 1998). Among the cardiovascular diseases, atherosclerotic diseases are 
the most frequently studied and are associated with patient outcome. Ischaemic heart 
disease was the cause of 53% of total mortality in a study performed in Scandinavia 15 
years ago (Lindholm et al, 1995) and these findings were still prevalent in a later report 
(Aakhus et al, 2004). However, several authors have recently emphasized the importance 
of functional cardiopathies such as congestive heart failure on patient outcome (Rigatto et 
al, 2002).  
The high incidence of cardiovacular events and mortality in renal transplant recipients has 
been attributed to the increased presence of traditional (Ojo, 2006) and nontraditional risk 
factors (Ducloux et al, 2004, De Mattos et al, 2006). As traditional risk factors do not fully 
explain the high cardiovascular risk it has been postulated that some of these risk factors, 
age, diabetes and smoking, could have a higher deleterous impact in transplant recipients 
than in the general population (Kasiske et al, 2000a). Other authors consider that transplant 
related (De Mattos et al, 2006) and nontraditional or emergent factors, hyperhomcysteinemia 
and inflammation, could play a predominant role in the appearance of cardiovascular 
events (Ducloux et al, 2004). Progressive chronic graft dysfunction and death with 
functioning graft are the most important causes of graft loss (Matas et al, 2002, Collins et al, 
2008)  and cardiovascular diseases are the leading cause of mortality in renal transplant 
recipients dying with a functioning graft (Pilmore et al, 2010). Consequently decreasing 
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cardiovascular mortality could improve patient and graft outcomes (Howard et al, 2002, 
Marcén et al, 2001, Morales, 2008, Vanrenterghem et al, 2008).   
The present chapter reviews the cardiovascular diseases which affect renal transplant 
recipients and their impact on patient mortality, the risk factors associated with these 
complications and the therapeutical strategies to improve patient and graft outcomes.  
2. Cardiovascular diseases 
Renal transplant recipients are not healthy individuals. They have a past history of chronic 
renal failure and dialysis therapy, both having negative impact on cardiovascular risk and 
they present variable chronic renal failure stages.  All cardiovascular diseases; 
atheriosclerotic and functional cardiopathies can affect transplant recipients  (Table 1). 
 
Atheroesclerotic diseases Functional cardiopathies 
    Coronary artery diseases 
    Cerebrovascular diseases 
    Peripheral vascular diseases 
    Congestive heart failure 
    Left ventricular hypertrophy 
    Arrhythmias 
Table 1. Most common cardiovascular diseases affecting transplant recipients 
As in the general population, cardiovascular diseases are important causes of morbidity and 
mortality in renal transplant recipients.  Heart diseases and cerebrovascular diseases 




Fig. 1. Causes of mortality in 224 renal transplant recipients with functioning graft 
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2.1 Atherosclerotic diseases 
2.1.1 Coronary artery disease 
Coronary artery disease is the most frequent atherosclerotic disease in the general 
population and a leading cause of cardiovascular mortality. It is generally admitted that 
coronary artery disease is between 2 and 6 times more frequent in renal transplant 
recipients than in the general population (Aarkhus et al, 1999, Kasiske, 1988, Lentine et al, 
2005a, Marcén et al, 2006, Massy, 2001). A very high number of events occurring during 
the first weeks after transplantation have been attributed to surgical stress, 
immunosuppression and silent disease while the patient was on dialysis (Kasiske et al, 
2000, 2005, Lentine et al, 2005, Marcén et al, 2006). In a retrospective study from the USA, 
the prevalence of coronary artery disease, defined as acute myocardial infarction, 
coronary revascularization procedures, or death due to coronary disease, was 23% at 15 
years of follow-up and it was the cause of 18.7% of mortality (Kasiske et al, 1996). In a 
multicenter, retrospective study performed in Spain, the prevalence of coronary artery 
disease was 6.8% at 5 years (Marcén et al, 2006) and very similar findings have been 
reported from France (Doucloux et al, 2004), two low risk countries. Data from the United 
Network for Organ Sharing (UNOS) and United States Renal Data System (USRDS) 
registry showed that the prevalence of acute myocardial infarction was between 6%  to 11 
% at 3 years a 17% lower than that observed on waiting list patients (Kasiske et al, 2006, 
Lentine et al, 2005). Moreover, myocardial infarction has a poor prognosis   and is the 
cause of high mortality (Herzog et al, 1998, 2000, Morales, 2008).  
The diagnostic criteria and therapeutical measures must be those used in the general 
population and in patients with chronic renal failure (Murphy et al, 1998). As a high 
percentage of events occur in the first weeks or months after the procedure, efforts have to 
be made to prevent and treat coronary artery disease before transplantation. Several 
algorithms have been proposed in which patients are classified according to cardiovascular 
risk (Lentine et al, 2008b, Wang & Kasiske, 2010), but we have not yet the ideal diagnostic 
procedure for asymptomatic patients. 
2.1.2 Cerebrovascular diseases 
Cerebrovascular diseases include transient cerebral ischaemia, when focal neurologic 
symptoms resolve in 24 hours, and persistent neurological deficits documented by 
computed tomography or nuclear magnetic resonance. Patients with chronic renal disease 
have more severe atherosclerotic lesions in carotic arteries than the general population 
(Kennedy et al 2001).  This could explain the 5 to 10 times higher risk of having ischaemic or 
haemorragic events when compared with the general population (Seliger et al, 2002, 
2003a,b). In renal transplant recipients the annual incidence was from 0.5% to 2.3% (Abedini 
et al, 2009a, Aull-Watschinger et al, 2008, Cosio et al, 2005, Lentine et al, 2008a, Oliveras et 
al,2003), and ischaemic events predominated in a proportion of 2-3:1 compared with 
haemorragic events (Aull-Watschinger et al, 2008, Oliveras et al, 2003). In a long-term study, 
by actuarial analysis, 15% of patients who survived with a functioning graft for 15 years 
experienced a major crebrovascular event (Kasiske et al, 1996). The evolution of 
cerebrovascular diseases is poor and a mortality rate around of 50% three months after the 
event has been reported (Oliveras et al, 2003). In retrospective studies, cerebrovascular 
diseases were the cause of 5% to 8% of total mortality (Aull-Watschinger et al, 2008, Howard 
et al, 2002). Only the Assessment of Lescol in Renal Transplantation (ALERT) study has 
prospectively investigated these complications, the incidence was 8.8% during the 6.7 year 
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follow-up period, and 21% of the cerebrovascular events, 48% of haemorragic and 8% of 
ischaemic, were fatal and accounted for 9.9% of total mortality (Abedini et al, 2009a).  
2.1.3 Peripheral vascular disease  
The incidence and clinical outcome of this complication have been seldom studied in renal 
transplant recipients. The diagnostic criteria include: intermitent claudication, ulceration 
with long-vessel disease on flow studies, amputations, by-pass or percutaneous angioplasty. 
The frequency reported was variable. In an old study, in which only amputation or 
revascularization procedures were included, the cumulative incidence was 15% at 15 years 
(Kasiske et al, 1996). In other studies, the incidence increased with the length of follow-up, 
from 2.1% at 1 year to 5.9% at 10 years (Sung et al, 2000).  Data from the UNOS registry have 
shown a cumulative incidence of 20% in diabetic and 5% in nondiabetic patients at 3 years 
(Snyder et al, 2006). As the disease develops along years it is difficult to distinguish risk 
factors due to transplantation from those present before. The need of amputation is low 
about 2 to 3% (Sung et al, 2000). The disease by itself is not a cause of mortality but patients 
suffering from it have an increased risk of death with a functioning graft (Snyder et al, 2006, 
Sung et al, 2000).  
3. Functional heart diseases  
3.1 Congestive heart failure  
Congestive heart disease is defined as dysnea plus at least two of the following 
characteristics; increased yugular venous pressure, basal lung rales, lung hypertension in 
radiography or pulmonary edema (Harnett et al, 1995). In dialysis patients, congestive heart 
failure is 36 times more frequent than in the general population and it is a mortality risk 
factor (Collins 2002, Stack &Bloemberg, 2001).  Congestive heart disease has been studied 
less than coronary artery disease in the renal transplant population and it is associated with 
coronary artery disease in 30% of cases (Rigatto, 2003a,b). Its annual incidence was 3-5 times 
that of the general population, reached a cumulative incidence of 18.3% at 3years and was 
associated with poor graft function (Abbott et al, 2003b, Lentine et al, 2005, Rigatto, 2003a,b).  
It has a high impact on mortality, similar to that of coronary artery disease (Lentine et al, 
2005).  
3.2 Left ventricular hypertrophy 
There are two types of left ventricular hypertrophy; concentric ventricular hypertrophy and 
dilatation with or without hypertrophy. The first one is associated with volume overload 
and the second with aortic insuficiency or severe anemia. Both types are more frequent in 
patients in renal failure than in the general population, reaching 20-50% in patients with 
chronic renal failure (Levin et al, 1996, Tucker et al, 1997) and up to 70% in those on dialysis 
(Foley et al, 1995, McGregor et al, 1998). Several prospective studies have shown that left 
ventricular hypertrophy improved during the first two years after transplantation but it was 
still present in about 40% of renal transplant recipients (Rigatto et al, 2000, Teruel et al, 
1987). Factors related with no improvement were: age, left ventricular morphology, duration 
and severity of hypertension and time averaged pulse pressure (Rigatto et al, 2000). 
Moreover, renal transplant also improved ventricular function in most patients even in 
those with severe impairment (Parfrey et al 1995, Wali et al, 2005). However these findings 
have been recently questioned when cardiac structure was assessed by magnetic resonance 
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(Patel et al, 2008). Parameters of ventricular hypertrophy or impaired cardiac function were 
associated with increased risk of cardiovascular events and cardiovascular mortality in renal 
transplant recipients (Aull-Watschinger et al, 2008, McGregor et al, 2000). In a 
nonrandomized study, conversión from CNI to sirolimus regressed left ventricular mass 
thickness regardless of blood pressure changes, thus suggesting non-hemodynamic-effect 
mechanisms on the left ventricular mass (Paoletti et al, 2008).  
3.3 Arrhythmias  
Atrial fibrilation is the most common cardiac rythm disorder in the general population and 
in patients on dialysis (Harnett et al 1995, Zebe 2001). Data from renal transplant recipients, 
despite being a high  risk population due to the pre-transplant history and the high 
prevalence of risk factors related to this complication such as hypertension and obesity, 
have only been recently reported. Registry studies from the USA have shown a cumulative 
prevalence around 7 % at 3 years (Abbott et al, 2003a, Lentine et al, 2006). Risk factors for 
postransplantation atrial fibrilation include older age, male gender, renal failure for 
hypertension, and coronary artery disease. As in the general population atrial fibrilation 
was associated with an increased cardiovascular mortality, up to 3 times higher than 
patients without the disease (Abbott et al, 2003, Lentine et al, 2006).  
4. Cardiovascular risk factors 
Three types of cardiovascular risk factors are generally identified in transplant recipients 
(Table 2). 1) Traditional risk factors are those which in the general population are associated 
with cardiovascular diseases, and their treatment decreases the incidence of these 
complications. They include; older age, hypertension, hypercholesterolemia, diabetes 
mellitus, tobacco smoking and obesity. Their incidence is mostly increased in advanced 
CKD stages (Ansell et al, 2007, Karthikeyan et al, 2004, Marcén et al, 2005). 2) Risk factors 
associated with the transplant; anaemia, graft dysfunction and related complications, 
proteinuria, and immunosuppression. Finally,3), non-traditional or emergent factors such as 
hyperhomocysteinemia and chronic inflammation. 
 



















Inflammation   
 
Table 2. Cardiovascular risk factors 
4.1 Traditional risk factors  
4.1.1 Age and sex  
Older age is a nonmodifiable cardiovascular risk factor in the general population. In renal 
transplant recipients it was associated with an increased risk for cardiovascular 
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atherosclerotic diseases; ischemic heart disease, cerebrovascular disease,  and peripheral 
vascular disease (Kasiske et al, 1996, Kasiske et al, 2006, Marcén et al, 2006, Oliveras et al, 
2003, Rigatto et al, 2002, Snyder et al, 2006), and also for functional heart diseases; 
congestive heart failure, left ventricular hypertrophy and arrhythmias (Abbott et al, 2003, 
Lentine et al 2006, Rigatto et al, 2000, Rigatto et al, 2002).  Male gender is a risk factor for 
ischemic heart disease and peripheral vascular disease (Kasiske, 1988, Rigatto et al, 2002, 
Kasiske et al, 2006, Marcén et al, 2006, Snyder et al, 2006) and female gender for 
cerebrovascular disease and congestive heart failure (Abbott et al, 2003, Lentine et al, 2008a).  
4.1.2 Hypertension  
It is a common complication in renal transplant recipients. Its prevalence varies between 70 
and 90%. There are several causes and mechanisms of high blood pressure and many 
patients have several of them. A previous history of hypertension, artery graft stenosis, the 
own recipient kidneys, overweight, chronic graft dysfunction and immunosuppressive 
agents such as calcineurin inhibitors (CNIs), cyclosporine and tacrolimus, are the conditions 
generally associated with post-transplant hypertension (Koomans & Ligtenberg, 2001, 
Zhang et al, 2003). Among CNIs, cyclosporine seems to increase blood pressure more than 
tacrolimus (Ligtenberg et al, 2001). It has been associated with an increased risk of ischemic 
heart disease, congestive heart failure, left ventricular hypertrophy (Rigatto 2002) and with 
mortality (Kasiske et al 2004, Fernández-Fresnedo et al, 2005). 
One characteristic of post-transplant hypertension is the lack of control despite treatment. In 
a study of 1295 patients, only 12.4% had a normal blood pressure one year after grafting and 
more than 95% of them were on antihypertensive therapy (Kasiske et al, 2004).  Others 
found in their series a higher number of patients with normal blood pressure without 
therapy (26.0%) but they also reported that 32.0% of patients had uncontrolled blood 
pressure while they were on treatment (Tutone  et al, 2005). Cross-sectional studies have 
shown that between 60 to 100% of patients according to the stage of graft failure had a blood 
pressure above 130/80 mm Hg and most of them were on antihypertensive therapy 
(Karthikeyan et al, 2004, Marcén et al, 2009a).  
There are not specific blood pressure levels for renal transplant recipients and the reference 
values are those of the general population. As the renal transplant recipients are considered 
a high risk population for cardiovascular diseases, a blood pressure of 130/80 mm Hg has 
been recommended. Treatment includes changing life style, reducing the diet sodium 
intake, physical activity, low consumption of alcohol and antihypertensive agents 
(Choubanian et al, 2003). There are no specific antihypertensive agents to treat post-
transplant hypertension and all agents can be used. The prescription has to be done taking 
into account the characteristic of each patient (KDIGO, 2009, Park & Luan, 2005). Most 
patients need to be treated with several antihypertensive agents. Studies in which 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers have been 
compared with other antihypertensive agents have shown controversial results, and there 
are no studies in which the superiority of one agent over the others on patient survival has 
been definitively established (Opelz et al, 2006, Hiremath et al, 2007). There are not 
randomized, prospective studies that have demonstrated the beneficial effects of controlling 
blood pressure in renal transplant recipients, but it has been assumed that they would be 
similar to those obtained in the general population. However, retrospective registry studies 
have shown that decreasing blood pressure even several years after hypertension 
appearance was associated with a better patient outcome (Opelz et al, 2005).  
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4.1.3 Dyslipidemia 
Lipid disorders are more common in renal transplant recipients than in the general 
population and include high levels of cholesterol and triglycerides. Also frequent are high 
levels of LDL-cholesterol, lipoprotein (a) and apolipoprotein B, while HDL-cholesterol can 
be high, normal or low. Hypercholesterolemia, total serum cholesterol above 200 mg/dl and 
LDL-cholesterol above 100 mg/dl, have been observed in up to 90 % of patients (Aakhus et 
al, 1996, Hricik et al, 1994).  Several factors have been associated with hyperlipidemia; 
genetic predisposition, body weight gain, graft dysfunction, proteinuria, diabetes, 
immunosuppressive and antihypertensive agents (Massy & Kasiske, 1996). 
Among immunosuppressive agents, corticosteroids, CNIs and mammalian target of 
rapamycin inhibitors (mTORs), sirolimus and everolimus, are those most frequently 
associated with hyperlipidemia. The mechanisms of corticosteroid-induced hyperlipidemia 
are through promoting insulin resistence and hyperinsulinism, reduction of lipoprotein 
lipase activity, overproduction of triglycerides and secretion of VDLD-cholesterol (Hricik et 
al, 1994).   CNIs inhibit bile acid synthesis and binding of the drugs to the LDL-cholesterol 
receptor with reduction of its activity. Also a decrease in lipoprotein lipase activity and 
impairment of LDL-cholesterol catabolism may be involved (Moore et al, 2001). These 
effects seem to be more prominent with cyclosporine than with tacrolimus (Ligtenberg et al, 
2001, Moore et al, 2001, Vincenti et al, 2002). mTORs are the agents with stronger 
hyperlipidemic effect (Kasiske et al, 2008),   which is  more accentuated in those patients also 
treated with cyclosporine than in those treated with tacrolimus (Ciancio et al, 2004). The 
pathogenesis of  mTOR  dyslipidemia is unclear.  A reduced catabolism of apo B100 could 
be the cause of increased triglycerides and cholesterol and decreased lipoprotein lipase 
activity and increased free fatty acid levels may be contributing factors. Their effects are 
dose dependent and rapidly reversible (Kasiske et al, 2008, Webster et al, 2006). 
As in the general population, hypercholesterolemia and low HDL-cholesterol levels are 
associated with ischemic heart disease (Kasiske, 1988 Kasiske et al, 1996, Kasiske et al, 2006, 
Marcén et al, 2006, Rigatto et al, 2002).  The treatment of this complication may follow the 
recommendations given to the general population and confirmed by the transplant 
guidelines (KDIGO, 2009). It is important to begin with a rich diet of monosaturated fats, but 
diet therapy does not control hyperlipidemia and lipid-lowering agents have to be added. 3-
Hydroxy-3methylglutaryl coenzyme A reductase inhibitors (statins) are the elective 
pharmacologic agents in hypercholesterolemic patients. Fluvastatin, pravastatin and 
atorvastatin seem to have a more favourable safety profile over simvastatin and lovastatin. 
In patients with hypertriglyceridemia, gemfibrocil is the pharmacological agent of choice. 
Some observational studies have shown an association between statin therapy and better 
patient outcome (Cosio et al, 2002a, Wiesbauer et al, 2008). However, the Assessment of 
Lescol in Renal Transplantation (ALERT) study did not show differences in the primary 
compound end point, despite a reduction of 32% in the LDL-cholesterol blood levels at 5 
years follow-up, between recipients treated with fluvastatin compared with those on 
placebo (Holdaas et al, 2003). A later evaluation of the study showed the benefits of the 
treatment but only when statin therapy started in the first two years after transplantation 
and in low-risk recipients (Holdaas et al 2005, Jardine et al 2004). In case of statin intolerance 
or hyperlipidemia of difficult control, ezetimibe that blocks the cholesterol absorption in the 
brush border, alone or combined with statins, is an efficient and safe alternative (Buchanan 
et al 2006, Langone & Chuang, 2006).  
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4.1.4 Diabetes  
In the renal transplant recipients, two types of diabetes mellitus can be distinguished, 
diabetes mellitus as the cause of end-stage renal disease and new onset diabetes mellitus 
(NODAT).  The prevalence of diabetes mellitus as the cause of renal failure is variable 
among countries. In the USA, more than 20% of the patients on the waiting list or 
transplanted have diabetes mellitus as the cause of renal failure (Collins et al, 2008).  The 
incidence of NODAT varies between 2% to 50% in the first posttransplantation year 
according to the criteria used in its definition (Montori et al, 2002). When the American 
Diabetes Association criteria were used, the incidence of NODAT at 12 months was 13% and 
of glucose intolerance of 33% in a study performed at the Mayo Clinic (Cosio et al, 2005). 
Similar findings have been observed in a prospective study from Spain (Marcén et al, 2006).  
As the term NODAT does not include  states of impaired fasting glucose and impaired 
glucose tolerance which pose a cardiovascular threat similar to overt diabetes,  the term 
transplant associated hyperglycemia (TAH)  has  been proposed (Crutchlow & Bloom, 2008). 
The most common risk factors associated with  NODAT or TAH include: race, blacks or 
hispanics, older age, obesity, family history, hepatitis C  virus infection and some 
immunosuppressive agents such as corticosteroids, CNIs (tacrolimus) and mTORs 
(Crutchlow & Bloom, 2007, Montori et al, 2002).   
The effects of immunosuppresive agents on glucose metabolism have been widely reviewed 
(Heisel et al, 2004, Miller, 2002, Morales & Dominguez, 2006).  Both CNIs, cyclosporine and 
tacrolimus, cause NODAT by inducing insulin resistance or by impaired insulin secretion 
(Hornum et al, 2010). Early trials designed to compare the efficacy and security of 
cyclosporine and tacrolimus, and registry data showed a higher incidence of NODAT in 
patients treated with tacrolimus (Kasiske et al, 2003, Mayer et al, 1997, Vincenti et al, 2002) 
and more recent studies have confirmed these findings (Vincenti et al 2007). Also mTORs 
are associated with an increased risk of NODAT (Johnston et al, 2008). These agents induce 
hyperglucemia by impairing insulin-mediated suppression of hepatic glucose production, 
by ectopic triglyceride deposition leading to insulin resistance, or by direct β cell toxicity 
(Crutchlow & Bloom, 2007). 
Single centre and registry studies have shown the association of NODAT with acute 
myocardial infarction, cerebrovascular events and mortality (Cosio et al 2002b, 2005, 2008, 
Kasiske et al 2003, Lentine et al, 2005, 2008). The treatment has the objective of preventing 
the symtoms due to uncontrolled hyperglucemia and the microvascular complications as the 
transplant recipients develop identical complications as the nontransplanted diabetic 
patients (Burroughs et al, 2007). The guidelines of the American Diabetes Association and 
the Joint Nacional Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure for patients with type 2 diabetes have been recommended (Haffner SM 
2003).  
4.1.5 Tobacco  
The effects of tobacco on the health in the general population are well known. It is a risk 
factor of cardiovacular diseases, malignancies and respiratory diseases (Bartecchi et al, 
1994). About 25% of the renal transplant population are active smokers after transplantation 
(Cosio et al 1999, Kasiske & Klinger, 2000, Zitt et al, 2007).  In transplant recipients, tobacco 
was associated with cardiovascular diseases and mortality (Kasiske & Klinger, 2000). It has 
been reported that the negative impact of tobacco on health disappeared after five years, 
and some authors emphasize that efforts have to be made to convince the patients about the 
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benefits of avoiding smoking. There are few data about the influence of transplant on toxic 
habits, but some studies suggest that transplantation constituted a strong reason to give up 
smoking (Banas et al, 2008).  
4.1.6 Obesity  
Obesity is a growing health problem in the general population. Epidemiological studies 
have shown its association with a higher morbidity and mortality due to cardiovascular 
diseases (Allison et al, 1999). Transplant recipients have a tendency to gain body weight 
mostly in the first year after grafting. In a study performed in our Unit, the mean body 
weight gain in the first year was 5 kg or 8.7 % of the body weight at the time of 
transplantation and the percentage of obese patients increased nearly two fold, from 6.5% to 
11.7% (Marcén et al, 2007).  Inappropriate dietary habits, decreased physical activity, and 
increased appetite as a result of well-being and corticosteroid therapy are among the causes 
of owerweight and obesity after transplantation. 
Both body weight gain and obesity (body mass index >30 kg/m2) are associated with an 
increased risk  for NODAT, hypertension, hyperlipidemia and metabolic syndrome which 
are cardiovascular risk factors (Armstrong et al, 2005, El-Agroudy et al 2004). The effects 
of weight gain and obesity on graft and patient outcome are controversial. Some authors 
do not find that the complication has any impact on patient mortality (Chang et al 2007, 
Marcén at al, 2007, Massarweh et al, 2005). However, other studies and registry data have 
shown their negative impact on patient survival due to an increased cardiovascular and 
infectious mortality (Aalten et al, 2006, El-Agroudy et al 2004, Meier-Kriesche et al, 2002). 
In our opinion, controlling weight gain and weight reduction in patients with marked 
obesity seems to be a goal to improve well-being and outcomes in renal transplant 
recipients.  
4.2 Risk factors associated with transplantation  
4.2.1 Anaemia  
Post-transplant anaemia  is a common complication that has only been recently studied and 
considered. Its prevalence depends greatly on the definition criteria and the time post-
transplant. Nowadays, there is a trend toward the use of the World Health Organization 
criteria which define anaemia as serum haemoglobin less than 12 g/dl in women and less 
than 13 g/dl in men. The prevalence of anaemia is about 90% during the first posttransplant 
weeks and decreases to 25% to 35% at 12 months and remains stable or slightly increases 
thereafter (Kamar et al, 2008, Vanrenterghem et al, 2003, Yorgin et al, 2002). In cross-
sectional studies the prevalence of anaemia reached more than one third of patients and it 
was severe, serum haemoglobin below 11 g/dl, in about 10% (Karthikeyan et al, 2004, 
Marcen et al, 2009a, Molnar et al, 2007, Vanrenterghem et al, 2003). The origen of anaemia is 
multifactorial and graft function is the most important factor (Shah et al, 2006, 
Vanrenterghem et al, 2003, Yorgin et al, 2002). However, it does not completely explain post-
transplant anaemia, as renal transplant recipients have more severe anaemia for each 
chronic renal disease stage when  compared with nontransplantation subjects (Chadban et 
al, 2007). Several immunosuppressive agents such as azathioprine, mycophenolate mofetil 
(MMF), enteric coated mycophenolic acid (EC-MPA) and mTORs  may cause anemia due to 
bone marrow toxicity or to disorders on iron homeostasis (Augustine et al, 2004, Fishbane et 
al, 2009, Vanrenterghem et al, 2003,  Wang et al, 2004). The combination of MMF or EC-MPA 
with mTORs is specially toxic for the bone marrow (Hricik, 2003, Rigatto, 2006). Other 
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medications as angiotensin converting enzyme inhibitors and angiotensin receptor blockers 
are known to cause anaemia and should be cautiously used. 
Recent studies have shown an association between anaemia and graft survival, 
cardiovascular diseases and mortality. Post-transplant anaemia seems to be a risk factor of 
congestive heart failure and of left ventricular hypertrophy but not of ischaemic heart 
disease (Borrow et al, 2008, Rigatto et al, 2002, 2003b). In addition, anaemia has been 
associated with increased mortality in some studies (Chhabra et al, 2008, Imoagene-Oyedeji 
et al, 2006, Kamar et al, 2008, Molnar et al, 2007) but not in others (Winkelmayer et al, 2006). 
The treatment of anaemia must follow the recommendations given for patients with chronic 
kidney disease in the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines 
(KDIGO, 2009). Iron supplementation and erythropoiesis stimulant agents should be 
administered to maintain serum haemoglobin between 11 and 12 g/dl.  
4.2.2 Graft dysfunction  
Renal function measured by the estimated glomerular filtration rate (eGFR) is a 
cardiovascular risk factor in the general population (Go et al, 2004). An important number of 
renal transplant recipients have different stages of renal failure (Figure 2), and at least two 
thirds have chronic renal failure defined by an eGFR below 60 ml/min/1.73m2 (Ansell et al, 
2007, Karthikeyan et al, 2004, Marcén et al, 2005). As cardiovascular diseases are the leading 
cause of renal transplant recipient mortality, it seems logical to think in the existence of 
some links between premature cardiovascular death and poor graft function. Registry and 
prospective studies have demonstrated a correlation betwen serum creatinine and 
cardiovascular events or cardiovascular mortality (Fellstrom et al, 2005, Meier-Kriescheet al, 
2003, Pilmore et al, 2010, Soveri et al, 2006). However, for other authors the increased 
cardiovascular risk of patients with poor graft function is mostly due to the effects of 
hypertension and anaemia than to graft failure itself (Rigatto et al, 2002). Moreover, 
uncontrolled hyperparathyroidism mostly in recipients with poor graft function may be a 
risk factor for progression of coronary artery calcification (Mazzaferro et al, 2009). The 
treatment of renal dysfunction includes the control of hypertension and dyslipidemias 
(Arias et al, 2005, Opelz et a, 2005, Wiesbauer et al, 2008) as well as the use of non-
nephrotoxic immunosuppressive agents as MMF, EC-MPA and belatacept and dose 
reduction or withdrawal of CNIs.  
The prevalence of proteinuria in the renal transplant recipients is between 7.5 and 45% 
(Knoll, 2009). It is a risk factor of progressive renal function loss and of cardiovascular 
disease in nontransplantation patients. Retrospective studies have reported that proteinuria 
is an important predictor of cardiovascular events and mortality in renal transplant 
recipients (Fernandez-Fresnedo et al, 2002, Roodnat 2001). It is important to note that 
proteinuria is frequently associated with graft dysfunction, hypertension and obesity and 
the effects of proteinuria on cardiovascular events could be mediated by these conditions or 
viceversa. Treatment of proteinuria includes control of hypertension, maintaning blood 
pressure levels below 120/80 mm Hg, of dyslipidemias and of overweigth, and avoiding 
immunosuppressive agents associated with proteinuria as mTORs (Amer & Cosio, 2009). 
Angiotensin converting enzime inhibitors and angiotensin receptor blockers are the elective 
agents of treatment of hypertension in patients with proteinuria because of their 
antiproteinuric effects. However, these agents can deteriorate graft function and increase the 
severity of anaemia, both cardiovascular risk factors as well. Moreover, there are no 
definitive studies which support the effectiveness of this treatment.  
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Fig. 2. Distribution of chronic kidney disease stages at 12 months  in  447  renal transplant 
recipients  (Ramón y Cajal Hospital) 
4.2.3 Immunosuppression  
The effects of immunosuppressive agents in cardiovascular risk factors have been 
previously reviewed (Miller, 2002, Marcén, 2009b, Morales & Dominguez-Gil, 2006). In 
addition, the impact of these agents on each cardiovascular risk factor has already been 
described.  Corticosteroids and CNIs are the agents with worst cardiovascular risk profile, 
increasing the incidence and severity of traditional risk factors such as hypertension, 
hyperlipidemia, diabetes and obesity. CNIs also are nephrotoxic and cause graft function 
impairment. mTORs increase the risk of anaemia, hyperlipidemia,  diabetes and proteinuria 
(Webster et al, 2006, Schena et al, 2009). MMF and EC-MPA may increase the risk of anaemia 
but have no impact in the other cardiovascular risk factors. Combinations of CNIs with 
MMF and EC-MPA or with mTOR allow corticosteroid withdrawal without harm.  On the 
other hand, MMF and EC-MPA and mTORs alone or in combination can be used for CNI 
dose reduction or withdrawal. All these strategies have been shown to be effective in 
improving cardiovascular risk but there are no prospective studies in which this 
improvement is followed by a lower incidence of cardiovascular events or mortality (Schena 
et al, 2009). Among the new immunosuppressive agents, belatacept improved short-term 
cardiovascular risk profile and graft function when compared with cyclosporine (Vincenti et 
al, 2010, Durrbach et al 2010). However, phase II trials with tasocitinib have shown no 
improvement in hyperlipidemia and blood pressure when compared with patients who 
received tacrolimus (Busque et al, 2009).  
4.3 Emergent risk factors 
4.3.1 Hyperhomocysteinemia  
Homocystein is a sulfur amino acid produced in all cells, and hyperhomocysteinemia has 
been considered a cardiovascular risk factor in the general population. 
Hyperhomocysteinemia is present in around 60% to 70% of renal transplant recipients. 








Stage 1 Stage2 Stage 3 Stage 4 Stage 5
%
www.intechopen.com
 Understanding the Complexities of Kidney Transplantation 154 
and treatment with CNIs (Bostom et al, 1999, Ducloux et al, 2000, Friedman et al, 2002).  The 
impact of homocystein levels on cardiovascular events is controversial. Some authors found 
an association between the homocystein levels and cardiovascular diseases (Ducloux et al, 
2000, 2004) and a prospective study has shown that homocystein levels above 12 μmol/l 
were associated with  2.44 times increased mortality (Winkelmayer et al, 2005). Other 
authors have not found this association (Hagen et al, 2001). The treatment consists in the 
administration of folic acid supplements (5 mg/day) even with normal folic acid levels 
(Fernandez-Miranda et al, 2000). The efficacy of this therapy in the prevention of 
cardiovascular events has been examined in the Folic Acid for Vascular Outcome Reduction 
in Transplantation (FAVORIT). This trial should contribute to answer this question (Bostom 
et al, 2009).   
4.3.2 Inflammation  
C-reactive protein (CRP) is an acute phase marker of inflammation. It is produced by the 
liver under control of several citokines. In the general population, C-reactive protein is 
associated with obesity and poor renal function (Stuveling et al, 2003). It is also a negative 
predictor of acute myocardial infarction, cerebrovascular disease and cardiovascular 
mortality (Ridker et al, 1997). In renal transplant recipients, its levels are associated with 
graft function, waist circumference and smoking (Van Ree et al, 2005).  The association 
between graft function and C-reactive protein levels could be explained by the situation of 
chronic low-grade inflammation, by being a marker of graft-mediated immune response or 
by a decreased renal excretion. As in the general population, it has been considered a risk 
factor of cardiovascular disease and mortality (Ducloux et al 2004, Winkelmayer et al 2004). 
Data from the ALERT study have confirmed the previous findings, baseline levels of CRP as 
well as of IL-6, another inflammation marker, were independently associated with major 
cardiovascular events and all-cause mortality (Abedini et al, 2009b). Results from a 
retrospective study have shown an association between MMF therapy and less 
inflammation than other immunosuppressive agents (Wong et al, 2007).  
5. Therapeutical strategies  
The management of each particular cardiovascular disease in  renal transplant recipients 
should be similar to  that used in the general population. In addition, clinical trials have 
demonstrated that cardiovascular events and cardiovascular mortality have been reduced 
by controlling blood glucose, lipid levels and blood pressure in the general population. As 
interventional studies are lacking in the transplant population, it seems reasonable to 
extrapolate these findings to transplant recipients. However, transplant recipients present 
differences from the general population, one of them is the high incidence of graft 
dysfunction. Preserving graft function has to be a goal in the management of transplant 
recipients and this could be partly accomplished by controlling the traditional 
cardiovascular risk factors and by a prudent use of immunosuppressive agents. CNIs 
minimization or withdrawal may be individually considered. Additional interventions such 
as treatment of anaemia with erytropoyesis stimulating agents could help in the prevention 
of cardiovascular diseases but the optimal haemoglobin threshold has to be determined. The 
benefits of lowering homocysteine levels have not been proved. In addition, long-term 
interventional studies should be performed in order to improve graft and patient outcomes 
(Table 3). 
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Control of cardiovascular risk  
factors 
Preserving graft function Treating emergent factors 
   Blood pressure  
   Dislipidemias 
   Diabetes 
   Smoking 
   Obesity 
   Anaemia 
   Minimization/avoidance 
of CNIs 
   Control of proteinuria 
   Folic acid supplements 
   Aspirin 
Table 3. Prevention and treatment of cardiovascular diseases after transplantation. 
6. Summary 
Cardiovascular diseases are common after transplantation. Coronary vascular disease, 
cerebrovascular disease and congestive heart failure are the diseases most commonly 
associated with mortality. The increased incidence of cardiovascular events could be partly 
explained by the high prevalence of traditional risk factors which are not adequately 
controlled and by the presence of renal dysfunction. Pretransplant evaluation of candidates, 
control of traditional risk factors and preservation of graft function should be the measures 
taken to improve patient outcome. The control of traditional risk factors has been effective in 
the reduction of cardiovascular events in the general population and there are no reasons to 
believe that it does not work in the transplant population. In addition, adequate control of 
traditional risk factors could preserve progression of graft failure. A prudent use of 
immunosuppressive agents could also help to improve the cardiovascular risk profile and 
graft function. The benefits of additional interventions need to be proved. 
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